ENTPD1 and hepatocellular carcinoma: The study highlights the clinical significance of exosomal circTMEM181 in HCC and suggests that targeting CD39 on macrophages to inhibit the ATP-adenosine pathway could overcome anti-PD1 therapy resistance in HCC [106].